Some tumours interact with specific immune checkpoints (i.e. PDL-1 and CTLA-4) directly to suppress T-cells and targeting these mechanisms has shown marked responses to therapy and improved prognoses in several tumour types; indeed, these are undoubtedly the most clinically mature class of immunotherapies available to date 96–98. Here, CTLA4 is linked to neoplasm.